/
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system ( CNS ) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms.
The business is unprofitable at the operating level (-585.20% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1181.3% YoY with margins expanding 10348.5pp.
Negative free cash flow of -$38M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$7M
▲ +1181.3% YoY
Net Income (TTM)
-$24M
▲ +34.1% YoY
Op. Margin
-670.25%
▲ +10348.5pp YoY
ROIC
-31.18%
▲ +22.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$42M
▲ +31.6% YoY
Op. Cash Flow (TTM)
-$42M
▲ +31.5% YoY
Net Debt
-$142M
Net Cash Position
Cash & Equiv.
$156M
5Y CAGR: -10.5%
Continue Research